To see the study designs for references 1-5 and 11-14 below, please see the  Study Designs  page.

1. Black DM, Thompson De, Bauer DC et al, for the FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85(11):4118-4124.

2. Quandt S, Thompson D, Hochberg M. Consistency of effect of alendronate on reduction in risk of hip and forearm fractures: A meta-analysis. Poster presented at: 5th Workshop on Bisphosphonates; April 5–7, 2000; Davos, Switzerland.

3. Hosking D, Adami S, Felsenberg D et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin 2003;19(5):preprint 1-12.

4. Cranney A, Guyatt G, Griffith L et al. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23(4):570-578.

5. Yates AJ, Rodan GA. Alendronate and osteoporosis. DDT 1998;3(2):69-78.

6. Meunier PJ, Confavreux E, Tupinon I et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997;82(9):2784-2791.

7. Lees B, Garland SW, Walton C et al. Role of oral pamidronate in prevention bone loss in postmenopausal women. Osteoporos Int 1996;6(6):480-485.

8. Thiébaud D, Burckhardt P, Kriegbaum H et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997;103(4):298-307.

9. Actonel® [prescribing information]. Cincinnati, Ohio: Procter & Gamble Pharmaceuticals; May 2002.

10. Reid IR, Brown JP, Burckhardt P et al. Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346(9):653-661.

11. Pols HAP, Felsenberg D, Hanley DA et al for the Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporos Int 1999;9(5):461-468.

12. Levis S, Quandt SA, Thompson D et al, for the FIT Research Group. Alendronate reduces the risk of multiple symptomatic fractures: Results from the Fracture Intervention Trial. J Am Geriatr Soc 2002;50(3):409-415.

13. Hosking D, Adami S, Felsenberg D et al. Once weekly alendronate produces a greater decrease in bone resorption than daily risedronate. Poster presented at: World Congress on Osteoporosis (WCO); May 10–14, 2002; Lisbon, Portugal.

14. Lewiecki EM, Rosen C, Bockman RS et al. Alendronate 70 mg once weekly and alendronate 10 mg once daily preference study in postmenopausal women with osteoporosis. Poster presented at: American Society for Bone and Mineral Research (ASBMR) 23rd Annual Meeting; October 12–16, 2001; Phoenix, Arizona, USA.